Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$111.75M+0.6%$111.04M+21.2%$91.6M+54.5%$59.29M+1.4%$58.44M-18.4%
$56.3M+10.3%$51.05M-5.0%$53.75M+1.3%$53.05M+14.5%$46.33M+14.6%
$74.23M+8.1%$68.67M+1.8%$67.46M+0.3%$67.28M+27.7%$52.69M+9.4%
$251.68M+4.7%$240.31M+7.3%$224.02M+20.7%$185.58M+13.5%$163.49M-2.5%
$5.03M+1.8%$4.95M0.0%$4.95M-6.4%$5.28M+0.5%$5.26M-5.4%
$22.86M0.0%$22.86M0.0%$22.86M0.0%$22.86M0.0%$22.86M0.0%
$85.37M-3.1%$88.08M-3.0%$90.79M-2.9%$93.5M-2.8%$96.21M-2.7%
$392.01M+2.2%$383.53M+3.6%$370.19M+10.6%$334.69M+6.1%$315.45M-2.4%
$11.47M+273%$3.08M-52.9%$6.53M-31.0%$9.46M+49.0%$6.35M+177%
$118.59M+8.2%$109.57M-5.7%$116.2M+22.1%$95.17M+0.1%$95.07M-5.3%
$221.22M+0.4%$220.34M+0.4%$219.47M+0.4%$218.63M+0.4%$217.81M+0.4%
$379M+2.5%$369.84M-0.3%$371.05M+4.8%$353.99M+1.0%$350.58M-0.6%
$18K+5.9%$17K0.0%$17K+6.3%$16K0.0%$16K+6.7%
-$669.07M+0.3%-$671.31M+1.6%-$682.39M+0.1%-$683.01M-0.3%-$681.08M-1.4%
$13.01M-5.0%$13.69M+1,690%-$861K+95.5%-$19.3M+45.0%-$35.13M-18.6%
$392.01M+2.2%$383.53M+3.6%$370.19M+10.6%$334.69M+6.1%$315.45M-2.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Xeris Biopharma Holdings, Inc.'s total assets?
Xeris Biopharma Holdings, Inc. (XERS) holds $392.0M in total assets, up 24.3% year over year.
How much debt does Xeris Biopharma Holdings, Inc. have?
Xeris Biopharma Holdings, Inc. carries $258.6M in total debt against $13.0M of shareholders' equity, a debt-to-equity ratio of 19.87.
How much cash does Xeris Biopharma Holdings, Inc. have?
Xeris Biopharma Holdings, Inc. holds $111.8M in cash and equivalents.
Can Xeris Biopharma Holdings, Inc. cover its short-term obligations?
Its current ratio is 2.12 — current assets exceed current liabilities.
Where does Xeris Biopharma Holdings, Inc.'s balance sheet data come from?
Every line is extracted from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.